Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Acquired by ADAR1 Capital Management LLC

ADAR1 Capital Management LLC boosted its stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 15.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 841,541 shares of the company's stock after acquiring an additional 112,140 shares during the period. Mineralys Therapeutics accounts for about 2.1% of ADAR1 Capital Management LLC's holdings, making the stock its 11th biggest position. ADAR1 Capital Management LLC owned approximately 1.69% of Mineralys Therapeutics worth $10,359,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Franklin Resources Inc. grew its stake in shares of Mineralys Therapeutics by 17.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,745,513 shares of the company's stock valued at $21,138,000 after purchasing an additional 262,922 shares during the last quarter. Vanguard Group Inc. grew its position in Mineralys Therapeutics by 5.0% in the 4th quarter. Vanguard Group Inc. now owns 1,432,042 shares of the company's stock valued at $17,628,000 after buying an additional 68,811 shares during the last quarter. Jennison Associates LLC grew its position in Mineralys Therapeutics by 55.4% in the 4th quarter. Jennison Associates LLC now owns 1,082,006 shares of the company's stock valued at $13,319,000 after buying an additional 385,726 shares during the last quarter. Geode Capital Management LLC increased its stake in Mineralys Therapeutics by 6.6% in the 3rd quarter. Geode Capital Management LLC now owns 620,853 shares of the company's stock valued at $7,520,000 after buying an additional 38,527 shares during the period. Finally, JPMorgan Chase & Co. raised its position in Mineralys Therapeutics by 2,251.5% during the 4th quarter. JPMorgan Chase & Co. now owns 503,590 shares of the company's stock worth $6,199,000 after buying an additional 482,174 shares during the last quarter. 84.46% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Mineralys Therapeutics Stock Performance

MLYS stock traded up $1.21 during trading on Friday, reaching $13.40. 848,809 shares of the company were exchanged, compared to its average volume of 409,065. The stock's 50 day moving average price is $12.21 and its 200 day moving average price is $12.31. Mineralys Therapeutics, Inc. has a 52-week low of $8.24 and a 52-week high of $18.38. The company has a market cap of $841.32 million, a P/E ratio of -3.68 and a beta of -0.39.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.02. As a group, equities research analysts forecast that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current year.

Wall Street Analyst Weigh In

MLYS has been the topic of a number of recent analyst reports. Guggenheim reiterated a "buy" rating on shares of Mineralys Therapeutics in a research note on Monday, February 24th. The Goldman Sachs Group dropped their target price on Mineralys Therapeutics from $28.00 to $24.00 and set a "buy" rating on the stock in a research report on Thursday, February 13th. Finally, HC Wainwright raised their price target on Mineralys Therapeutics from $30.00 to $42.00 and gave the company a "buy" rating in a report on Wednesday, April 2nd.

Insiders Place Their Bets

In other Mineralys Therapeutics news, major shareholder Samsara Biocapital Gp, Llc acquired 600,000 shares of the company's stock in a transaction dated Thursday, March 13th. The stock was acquired at an average cost of $13.50 per share, with a total value of $8,100,000.00. Following the purchase, the insider now directly owns 5,674,916 shares in the company, valued at approximately $76,611,366. This trade represents a 11.82 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, insider David Malcom Rodman sold 55,771 shares of Mineralys Therapeutics stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $15.76, for a total value of $878,950.96. Following the transaction, the insider now owns 116,704 shares of the company's stock, valued at $1,839,255.04. This represents a 32.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 84,861 shares of company stock worth $1,142,937. 33.24% of the stock is owned by corporate insiders.

Mineralys Therapeutics Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.